Janus Henderson Group
INZY

Janus Henderson Group’s Inozyme Pharma INZY Stock Holding History

Janus Henderson Group’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,411,154
Closed -$3.81M – 2479
2022
Q3 		$3.81M Buy
1,411,154
+481,198
+52% +$1.74M ﹤0.01% 1068
2022
Q2 		$4.46M Buy
929,956
+409,193
+79% +$1.78M ﹤0.01% 864
2022
Q1 		$2.12M Buy
520,763
+395,610
+316% +$2.33M ﹤0.01% 1209
2021
Q4 		$857K Buy
+125,153
New +$1.08M ﹤0.01% 1579

Other funds holding INZY

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group's INZY Position: Q4 2022 in Review

Janus Henderson Group sold out of Inozyme Pharma (INZY) in Q4 2022, closing a stake of 1,411,154 shares — an estimated $3.81M sold.

Janus Henderson Group first reported a position in INZY in Q4 2021 and held it in 4 quarters. The position peaked at $4.46M in Q2 2022. 37 funds tracked by Wall St. Rank hold INZY as of Q4 2022.

  • Janus Henderson Group reported no remaining Inozyme Pharma position as of Q4 2022 after selling out during the quarter.
  • Janus Henderson Group sold 1,411,154 Inozyme Pharma shares in Q4 2022, an estimated $3.81M.
  • Janus Henderson Group first reported a position in Inozyme Pharma in Q4 2021 and held it in 4 quarters.
  • Janus Henderson Group's Inozyme Pharma position peaked at $4.46M in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2022.

Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.